M33 Growth, a Boston, MA-based venture and growth stage investment firm, closed its second fund, at $260m.
Limited partners in M33 Growth II include some of the nation’s top endowments, foundations and institutional investors, as well as founders and CEOs with whom the team has forged working relationships with over the past decade. It follows the firm’s $180m debut fund that closed in late 2017.
M33 Growth seeks to partner with founders and CEOs of companies who are using technology to solve critical, industry-specific problems and beat legacy incumbents in their vertical markets in the software, healthcare and services sectors throughout North America.
Led by Gabe Ling, Brian Shortsleeve and Michael Anello, M33 Growth invests growth capital and applies its operational experience to optimize go-to-market teams and execute on strategic acquisitions. Since the launch, M33 Growth has invested in six bootstrapped companies driving productivity and automation in a variety of B2B software and services applications.
The firm is supported by a team of 15 out of its Boston headquarters.
The current portfolio includes AssuriCare, RHI Group, The Oncology Institute, TITAN Cloud and Waterfield Energy.
FinSMEs
22/02/2020